Active Biotech AB (SE:ACTI)
:ACTI
ACTI Stock Chart & Stats
kr0.04
<kr0.01(1.97%)
At close: 4:00 PM EST
kr0.04
<kr0.01(1.97%)
Day’s Range― - ―
52-Week Rangekr0.04 - kr0.27
Previous CloseN/A
Volume903.68K
Average Volume (3M)4.56M
Market Cap
kr116.25M
Enterprise Value-kr7.77M
Total Cash (Recent Filing)kr65.10M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,636,067,100
10 Day Avg. Volume2,218,804
30 Day Avg. Volume4,558,826
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetA debt position of zero in 2025 and modest leverage reduce refinancing and interest risks, preserving financial flexibility. This cleaner balance sheet is a durable buffer that supports continued R&D activity, partnership negotiations, and optionality on financing over the coming months.
Improving Cash Burn And Narrowed Operating LossesOperating losses and cash burn have declined versus 2022–2023, reflecting better cost discipline or program prioritization. If sustained, this reduces near-term financing needs, extends runway for clinical/partnering activities, and strengthens negotiating leverage with potential collaborators.
Partnering/out-licensing Business ModelA strategy focused on out-licensing and partnerships lowers fixed costs and capital intensity compared with commercial manufacturing. This durable model transfers late‑stage development and commercialization expenses to partners while providing milestone and royalty upside.
Bears Say
No Revenue And Persistent Net LossesZero reported revenue from 2021–2025 coupled with persistent net losses means the company lacks an internal product income stream. This structural absence of recurring revenue increases dependence on milestone deals or financing and steadily erodes shareholder equity over time.
Negative Operating Cash Flow And Funding DependenceSustained negative operating cash flow (≈-32.4M in 2025) implies ongoing cash burn and a continued reliance on external funding or milestone receipts. This creates dilution or financing risk and constrains the firm's ability to advance multiple programs without partner support.
Very Small Internal Team Limits CapacityA headcount of six implies limited internal bandwidth to run multiple clinical or development programs, increasing dependence on CROs and partners. This structural constraint can slow program timelines, raise outsourcing costs, and concentrate execution risk externally.
Active Biotech AB News
ACTI FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was kr0.04 and its highest was kr0.27 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is kr116.25M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Feb 12, 2026. The company reported -kr0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.007.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 2,636,067,100 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -kr0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in SE:ACTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Medivir AB
―
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―